Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,484.80
(
-0.99%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
106.93
(
0.00%
)
Bitcoin
70,648.16
(
0.19%
)
News Focus
News Focus

Replies to post #152 on Enanta Pharmaceuticals Inc (ENTA)

Replies to #152 on Enanta Pharmaceuticals Inc (ENTA)
icon url

DewDiligence

12/10/13 9:55 AM

#153 RE: ronpopeil #152

My comments on the SAPHIRE-2 data: #msg-94817670.
icon url

DewDiligence

12/10/13 4:11 PM

#157 RE: ronpopeil #152

ABBV/ENTA’s SAPHIRE-2 data (#msg-94817670) are so strong that GILD can, realistically, only hope to match them rather than exceed them.

No one I know expected a 96% SVR rate in this patient pool (treatment-experienced GT1a/GT1b of whom 49% were prior null responders) without any hint of a safety or tolerability problem.